From the design to the clinical application of thromboxane modulators

Current Pharmaceutical Design
Jean-Michel DognéKe-He Ruan

Abstract

Arachidonic acid (AA) metabolites are key mediators involved in the pathogenesis of numerous cardiovascular, pulmonary, inflammatory, and thromboembolic diseases. One of these bioactive metabolites of particular importance is thromboxane A(2) (TXA(2)). It is produced by the action of thromboxane synthase on the prostaglandin endoperoxide H(2) (PGH(2)) which results from the enzymatic transformation of AA by the cyclooxygenases. It is a potent inducer of platelet aggregation, vasoconstriction and bronchoconstriction, and has been involved in a series of major pathophysiological conditions. Therefore, TXA(2) receptor antagonists, thromboxane synthase inhibitors and drugs combining both properties have been developed by different laboratories since the early 1980s. Several compounds have been launched on the market and others are under clinical evaluation. In the first part of this review, we will describe the physiological properties of TXA(2), thromboxane synthase and thromboxane receptors. The second part is dedicated to a description of each class of thromboxane modulators with the advantages and disadvantages they offer. In the third part, we aim to describe recent studies performed with the most interesting thromboxane modul...Continue Reading

Citations

Jun 28, 2012·Pharmacogenetics and Genomics·Chung-Ying K ChenLee-Ho Wang
Jul 24, 2012·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Sergio Montserrat-de la PazMaría Dolores García-Giménez
Nov 4, 2010·European Journal of Pharmacology·Frank StrittmatterMartin Hennenberg
Jun 17, 2008·The Journal of Nutritional Biochemistry·Angeles Fernández-ArcheValentina Ruiz-Gutierrez
Apr 1, 2008·Pharmacology & Therapeutics·Norimichi Nakahata
Nov 17, 2007·Current Opinion in Biotechnology·David C LambF Peter Guengerich
Jul 25, 2009·British Journal of Pharmacology·R L JonesD F Woodward
Mar 22, 2012·Medicinal Research Reviews·Valérie CapraG Enrico Rovati
May 25, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Eugenio RosadoJuan Carlos García-Pagán
Aug 7, 2013·Journal of Enzyme Inhibition and Medicinal Chemistry·Plínio Cunha SathlerHelena Carla Castro
May 21, 2008·Allergology International : Official Journal of the Japanese Society of Allergology·Hiroichi Nagai
Jan 8, 2014·Laboratory animal research·Ja-Young JangYun-Bae Kim
Apr 8, 2014·Laboratory animal research·Ja-Young JangYun-Bae Kim
Sep 21, 2013·American Journal of Physiology. Renal Physiology·Martin HennenbergChristian Gratzke
Apr 8, 2015·World Journal of Hepatology·Balasubramaniyan Vairappan
Mar 8, 2017·International Journal of Molecular Sciences·Yunqi WengKevin Yueju Wang
Aug 2, 2020·Journal of Translational Medicine·Darawan RinchaiDamien Chaussabel
Nov 9, 2011·Journal of Cardiovascular Pharmacology and Therapeutics·Harold J TingFadi T Khasawneh
Aug 12, 2020·International Journal of Biological Macromolecules·Ali Muhammed Moula Ali, Sri Charan Bindu Bavisetty
Sep 16, 2014·ACS Medicinal Chemistry Letters·Xiaozhao WangCarlo Ballatore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.